Aquestive Therapeutics (AQST) CEO Barber Sells $106K of Stock

Daniel Barber, the President and CEO of Aquestive Therapeutics, Inc. (AQST) sold 25,000 shares on October 15, 2026. The sale was planned and valued at approximately $105,600, with the shares sold at a price of $4.22 each.

Inside Daniel Barber's Trade

Barber's recent sale adds to a series of transactions. Earlier this year, he sold 25,000 shares on September 15, 2026, at $4.82 each, and another 25,000 shares on August 17, 2026, at $4.29 each.

Other Institutional Activity in Aquestive Therapeutics

Bratton Capital Management held steady with 9,810,958 shares of Aquestive Therapeutics. Blackrock Inc. increased its stake by 560,185 shares, bringing its total to 8,069,373 shares valued at about $30.5 million. Vanguard Capital Management added 140,864 shares, ending with 4,584,533 shares worth approximately $17.3 million. Federated Hermes also increased its holdings by 172,299 shares, totaling 3,112,561 shares valued at about $11.8 million.

Aquestive Therapeutics, Inc. Stock Down 5.4%

As of October 16, 2026, AQST was recently trading around $3.84, which is below its 50-day moving average of $4.72 and its 200-day average of $4.28. The stock is also about 49.1% below its 52-week high of $7.55, indicating a challenging market position.

Recent Earnings

In its trailing twelve months, Aquestive Therapeutics reported revenue of $54.1 million, with a year-over-year revenue growth of 38.1%. However, the company has a negative net margin of 144.6%. The next earnings report is set for November 4, 2026.

Insider Buying and Selling at Aquestive Therapeutics, Inc.

Daniel Barber has been active in selling shares, with his most recent sale of 25,000 shares on October 15, 2026. This follows several other sales earlier in the year, including a sale of 25,000 shares on September 15 for $120,488 and another 25,000 shares on August 17 for $107,168.

Analysts Set New Price Targets

On August 24, 2026, HC Wainwright & Co. reiterated their Buy rating for AQST, maintaining a price target of $10.00. The consensus among analysts is a strong buy, with a mean target price of $9.33 based on nine opinions.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. is a pharmaceutical company based in Warren, New Jersey. It focuses on developing and commercializing innovative drug delivery technologies. The recent insider trades and the company's performance highlight the challenges it faces in the healthcare sector.

Bottom Line

Investors should keep an eye on the upcoming earnings report on November 4, 2026, as well as further insider transactions. Barber's sales, while planned, reflect a dynamic situation within the company as it navigates its market challenges.